Articles related to CAR T-CELL THERAPIES

In a recent study involving patients with CD7-positive leukemia and lymphoma, an integrated approach of CAR T-cell therapy followed by haploidentical HSCT resulted in a one-year disease-free survival rate of 54%. This strategy highlights the potential for advanced therapeutic combinations to manage relapsed or refractory hematologic cancers effectively.

Explore the potential of CARv3-TEAM-E T cells in recurrent glioblastoma, a novel therapy showing promise with rapid tumor regression and no severe adverse effects in early clinical evaluation.

With more than 27,000 doses administered, CAR T-cell therapies represent a breakthrough in treating hematologic malignancies, though emerging reports of secondary T-cell cancers post-treatment highlight the importance of long-term patient monitoring and reporting.

Recent advances in CAR T-cell therapy show significant promise in treating both blood cancers and solid tumors, offering durable responses and extended survival rates for patients previously facing limited options.

CARsgen Therapeutics faces a critical juncture as the FDA places a clinical hold on three of its key CAR-T cell therapy candidates, highlighting the paramount importance of manufacturing standards in the realm of advanced oncology treatments.

Discover how CRISPR-engineered CD45 CAR T-cells could alter the treatment landscape for various blood cancers, offering a more versatile and less risky approach.